Game-Changer: Oral Therapy Non-Inferior to Intravenous for Low-Risk S. aureus Bloodstream Infections
18 Jan 2024 • Staphylococcus aureus bloodstream infection is commonly treated with at least 14 days of intravenous antimicrobials.
In a groundbreaking international trial, researchers have found that an early switch to oral antimicrobial therapy in low-risk Staphylococcus aureus bloodstream infections was non-inferior to the traditional intravenous approach in preventing complications related to the infection (including relapsing S. aureus bloodstream infection, deep-seated infection, and mortality attributable to infection) within 90 days.
However, it is necessary to carefully assess patients for signs and symptoms of complicated S aureus bloodstream infection at the time of presentation and thereafter before considering early oral switch therapy.
Source: The Lancet | Read full story